Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.

[1]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[2]  P. Pratt,et al.  Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. , 1992, European journal of pharmacology.

[3]  P. Silver.  8 – Inhibition of Phosphodiesterase Isoenzymes and Cell Function by Selective PDE5 Inhibitors , 1996 .

[4]  K. Ferguson,et al.  1 – Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods , 1996 .

[5]  T. Saeki,et al.  A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. , 1995, The Journal of pharmacology and experimental therapeutics.

[6]  G. Y. Lesher,et al.  Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. , 1994, The Journal of pharmacology and experimental therapeutics.

[7]  J. Beavo,et al.  Multiple cyclic nucleotide phosphodiesterases. , 1994, Molecular pharmacology.

[8]  R. Dundore,et al.  Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. , 1993, European journal of pharmacology.

[9]  P. Pratt,et al.  Lack of cross-tolerance between nitroglycerin and endothelium-derived relaxing factor-mediated vasoactive agents in spontaneously hypertensive rats. , 1993, European journal of pharmacology.

[10]  L. Ignarro,et al.  Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission , 1992 .

[11]  P. Silver,et al.  Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. , 1992, Basic research in cardiology.

[12]  G. Hasenfuss,et al.  Cellular and molecular alterations in the failing human heart. , 1992, Basic research in cardiology.

[13]  P. Pratt,et al.  N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast. , 1991, European journal of pharmacology.

[14]  S. Moncada,et al.  Characterization of the l‐arginine: nitric oxide pathway in human platelets , 1990, British journal of pharmacology.

[15]  P. Mehta,et al.  Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor. , 1989, The Journal of pharmacology and experimental therapeutics.

[16]  K. Kariya,et al.  Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. , 1989, Atherosclerosis.

[17]  R. Bentley,et al.  Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. , 1989, The Journal of pharmacology and experimental therapeutics.

[18]  F. Murad,et al.  Cyclic guanosine monophosphate as a mediator of vasodilation. , 1986, The Journal of clinical investigation.

[19]  R. Furchgott,et al.  Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. , 1986, The Journal of pharmacology and experimental therapeutics.